Deborah Cohen and James Raftery ask why one of the first drugs to be developed by a partnership between a charity and a drug company also ended up being one of the world’s most expensive drugs. Why didn’t such philanthropy lead to greater patient access?
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: